RioCan Real Estate Investment Trust T.REI.UN

Alternate Symbol(s): RIOCF

RioCan Real Estate Investment Trust is a Canada-based real estate investment trust. The Company owns, manages and develops retail-focused, mixed-use properties. Its portfolio includes leasing, development, and residential. The Company’s properties are held by various tenants, such as grocery, pharmacy, liquor, personal services, and specialty and value retailers. Its portfolio comprises approximately 187 properties with an aggregate net leasable area of approximately 33 million square feet. Its properties include 1293 Bloor Street West; 145 Woodbridge Avenue; 1556 Bank Street; 1650 -1660 Carling Avenue; 1860 Bayview; 1946 Robertson Road; 2422 Fairview Street, and others. Its properties for commercial lease, including grocery anchored, open air, mixed-use/urban, and enclosed centers. Its residential brand, RioCan Living, delivers purpose-built rental units and condos. 1293 Bloor Street West is located at the intersection of Lansdowne Ave & Bloor Street in Toronto.

TSX:REI.UN - Post by User

RioCan Real Estate Investment Trust > Beginning of the end

<< Previous

Bullboard Posts

Next >>

Comment by CANCDNon Dec 21, 2020 8:28am

59 Views

Post# 32151222

RE:RE:Beginning of the end

every single credible virologists has already said this is essentially a non issue for the vaccine. Changes in virus can make vaccine less or MORE effective. The efficacy for changing viruses is never a stagnant %. It fluctuates over the years and vaccines are slightly varied.

ohh well, I have a buy order in for 17.20.

gashole wrote: Good news, now if we can just get the markets to not panic over the new strain, we will be off to the races.. But the media has screwed that up with no basis or facts about whether the new strain is not taken care of with the vaccine, and it probably is........

canadian wrote: A team of researchers from Finland found that 91% of the peopletested for coronavirus antibodies still hadneutralizing antibodies six months after surviving COVID-19. The study suggests the immune response after COVID-19 is potent, and protection against reinfection might be long-lasting. The results are promising forvaccines, which have proven to elicit an immune response in clinical trials thats comparableor better than exposure to the pathogen.